Home › Blood Cancers › Kentucky › Lexington
Blood Cancers clinical trials in Lexington, KY
4 studies for Blood Cancers are looking for participants at sites in and around Lexington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- University of Kentucky/Markey Cancer Center, Lexington
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- CommonSpirit Saint Joseph Hospital - Lexington, Lexington
- Saint Joseph Radiation Oncology Resource Center, Lexington
- CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
- Quetzal Site 18, Lexington
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- University of Kentucky, Lexington
Blood Cancers trials in other cities
- Houston, TX46 studies
- New York City, NY26 studies
- Boston, MA25 studies
- Washington, DC19 studies
- Seattle, WA18 studies
- Baltimore, MD18 studies
- Los Angeles, CA17 studies
- Durham, NC16 studies
- Chicago, IL15 studies
- Philadelphia, PA14 studies
- Nashville, TN13 studies
- Columbus, OH13 studies
Other studies in Lexington
- Non-Small Cell Lung Cancer23 studies
- Lung Cancer18 studies
- Ovarian Cancer16 studies
- Prostate Cancer14 studies
- Cancer (all types)14 studies
- Breast Cancer14 studies
- Metastatic Cancer11 studies
- Colorectal Cancer11 studies
- Heart Failure11 studies
- Melanoma10 studies
- Acute Myeloid Leukemia10 studies
- Obesity10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.